I-BET-762: Precision BET Bromodomain Inhibition as a Tran...

2025-10-18

This thought-leadership article delineates the mechanistic edge and translational promise of I-BET-762, a selective BET bromodomain inhibitor, in modulating inflammation and ferroptosis. Integrating recent evidence, competitive landscape analysis, and workflow strategies, the piece offers actionable guidance for translational researchers seeking to leverage epigenetic regulation inhibitors for next-generation preclinical models and therapeutic innovations.